Genfit Dives Into Uncertain Late-stage NASH Trial
This article was originally published in Scrip
You may also be interested in...
Genfit CEO Pascal Prigent talks to Scrip about the company's high-profile trial failure in NASH and the pipeline pivot to various other drug candidates for rare liver diseases.
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.
Genfit SA is now pinning its hopes for elafibranor on primary biliary cholangitis after the dual PPAR alpha/delta agonist failed in its Phase III RESOLVE-IT trial for NASH.